EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation

David I Harriman iD, Alex Ng iD, Alan C Farney iD, Giuseppe Orlando iD, Colleen Jay iD, Amber Reeves-Daniel, Robert J Stratta iD

Clinical Transplantation · 2026-03 · 40 (3)

DOI: 10.1111/ctr.70495 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2026-03-05. Written by David I Harriman and 6 co-authors. Institution: Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Major MEDLINE topics: Alemtuzumab, Kidney Transplantation, Graft Survival, Graft Rejection. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

The anti‐CD52 monoclonal antibody alemtuzumab is used as an induction agent in kidney transplantation (KT) but remains understudied in septuagenarian recipients. The study purpose was to analyze the safety and efficacy of single‐dose alemtuzumab induction in septuagenarian deceased donor (DD) KT recipients.

Methods

Single center retrospective nonrandomized cohort review of septuagenarian DDKT recipients stratified by induction immunosuppression (single dose alemtuzumab versus multi‐dose rabbit anti‐thymocyte globulin [ATG]). Standardized management algorithms were used, and all patients received maintenance immunosuppression with tacrolimus/mycophenolate/steroids.

Results

From November 2003 to December 2024, 359 DDKTs were performed in septuagenarian recipients with either alemtuzumab ( n = 270) or ATG induction ( n = 89). Donor and recipient characteristics were largely comparable between the two groups. Five‐year patient (70.3% alemtuzumab versus 82.9% ATG, p = 0.054), graft (60.2% alemtuzumab versus 74.7% ATG, p = 0.04) and death‐censored graft survival (80.0% alemtuzumab versus 89.1% ATG, p = 0.11) rates favored the ATG cohort.

Conclusion

ATG induction was associated with improved survival outcomes in our cohort and may be the preferred induction agent in septuagenarians undergoing DDKT versus alemtuzumab. Given the findings of our study, caution is warranted with the use of alemtuzumab in elderly KT patients receiving triple maintenance immunosuppression.

Subjects

MeSH terms (MEDLINE)

AlemtuzumabKidney TransplantationGraft SurvivalGraft RejectionTissue DonorsKidney Failure, ChronicPostoperative ComplicationsHumansFemaleMaleRetrospective StudiesPrognosisFollow-Up StudiesMiddle AgedKidney Function TestsImmunosuppressive AgentsGlomerular Filtration RateRisk FactorsSurvival RateAdult

Author keywords

alemtuzumabdeceased donor kidney transplantelderly recipientsgraft survivalkidney transplantationpatient survivalseptuagenarians

Substances

AlemtuzumabImmunosuppressive Agents

Authors and institutions

  • Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Surgery, Section of Transplantation, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Internal Medicine, Section of Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

ORCID profiles: David I Harriman, Alex Ng, Alan C Farney, Giuseppe Orlando, Colleen Jay, Robert J Stratta

Cite

APA

Harriman, D. I., Ng, A., Farney, A. C., Orlando, G., Jay, C., Reeves-Daniel, A., & Stratta, R. J. (2026). Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation. Clinical Transplantation, 40(3). https://doi.org/10.1111/ctr.70495

Vancouver

Harriman DI, Ng A, Farney AC, Orlando G, Jay C, Reeves-Daniel A, et al. Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation. Clinical Transplantation. 2026;40(3). doi:10.1111/ctr.70495

BibTeX
@article{Harriman2026,
  author = {Harriman, David I and Ng, Alex and Farney, Alan C and Orlando, Giuseppe and Jay, Colleen and Reeves-Daniel, Amber and Stratta, Robert J},
  title = {Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation},
  journal = {Clinical Transplantation},
  year = {2026},
  volume = {40},
  number = {3},
  doi = {10.1111/ctr.70495}
}
Start for free →